tirzepatide consent Semaglutide and Weight Loss Client Form | Editable Weight Loss Consent Template | Glp 1 Medication Consent GLP-1 Informed Consent & Risk

A 2024 study presented at the American College of Rheumatology conference showed semaglutide users experienced 40 percent greater improvement in knee pain scores compared to placebo after 12 weeks, with continued gains through 52 weeks of observation

Yes, PlexusDx compounded semaglutide is HSA and FSA eligible, allowing you to use pre-tax healthcare funds to cover your monthly prescription

Clinical evidence shows that stopping semaglutide often leads to gradual weight regain, meaning long-term or indefinite use may be part of your plan

Importantly, this is a retrospective study and not a randomized controlled trial, which means that there could be reasons why people were prescribed semaglutide vs other treatments that impacted their subsequent likelihood of a AUD diagnosis